anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered GS as an option to assess for additional disease risk. The GS will be limited to evaluation of single gene disorders on a curated gene list developed by our multidisciplinary team of experts. This will include only pathogenic or likely pathogenic variants in genes associated with conditions with a well-defined phenotype that may include cognitive impairment or debilitating health conditions in childhood and/or conditions that will impact maternal, fetal, neonatal, or early childhood health management with significant perinatal or pediatric morbidity or mortality. GS test results will be reported to the research participant by a clinical geneticist or genetic counselor with expertise in exome sequencing. Participants may use this information for pregnancy management including termination of pregnancy. Participants will be offered analysis for secondary findings, as recommended by the American College of Medical Genetics and Genomics. Analysis and reporting of GS will be performed by the UCSF CLIA-certified Genomic Medicine Laboratory. Blood or saliva samples will be collected on both parents to allow trio GS to determine inheritance of any potentially significant fetal variants.

The project is exploratory in nature, with a goal of contributing to a growing body of evidence regarding the clinical utility of GS in the prenatal population.
Repeated sublethal hypoxia exposure induces brain inflammation and affects the initiation and progression of cognitive dysfunction. Experiments from the current study showed that hypoxic exposure downregulates PKA/CREB signaling, which is restored by forskolin (FSK), an adenylate cyclase activator, in both Neuro2a (N2a) cells and zebrafish brain. FSK significantly protected N2a cells from hypoxia-induced cell death and neurite shrinkage. Intraperitoneal administration of FSK for 5 days on zebrafish additionally led to significant recovery from hypoxia-induced social interaction impairment and learning and memory (L/M) deficit. FSK suppressed hypoxia-induced neuroinflammation, as indicated by the observed decrease in NF-κB activation and GFAP expression. We further investigated the potential effect of FSK on O-GlcNAcylation changes induced by hypoxia. Intriguingly FSK induced marked upregulation of the protein level of O-GlcNAc transferase catalyzing addition of the GlcNAc group to target proteins, accompanied by elevated O-GlcNAcylation of nucleocytoplasmic proteins. The hypoxia-induced O-GlcNAcylation decrease in the brain of zebrafish was considerably restored following FSK treatment. Based on the collective results, we propose that FSK rescues hypoxia-induced cognitive dysfunction, potentially through regulation of HBP/O-GlcNAc cycling.
Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
Participants with newly diagnosed EGFRvIII+ GBM with unmethylated MGMT promotor status will undergo leukapheresis for manufacturing of E-SYNC T cells at least 2 weeks after completion of tnon-interventional, standard of care radiation therapy. Participants receive cyclophosphamide IV and fludarabine IV on days -5, -4, and -3 and then receive E-SYNC T cells IV on day 0. Participants will receive a single infusion of drug product (DP) (5 x 10\^7 CAR+ T cells) and be monitored for safety, presence of and possible synNotch \> CAR-T priming of the DP in the peripheral blood.
Three different polymorphs of Bromfenac sodium consist of Form 1 (sesquihydrate), Form II (monohydrate) and Form III (anhydrous). These polymorphs may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. Form I may be prepared by crystallizingrecrystallizing amorphous Bromfenac sodium from a mixture of water, a dialkoxyalkane such as 1,2-dimethoxyethane and an anti-solvent such as an ether, preferably t-butyl methyl ether. Form II may be prepared by drying Form I under vacuum or by recrystallizing Form III from a mixture of water, a dialkoxyalkane such as 1,2-dimethoxyethane and an anti-solvent such as an ether, preferably t-butyl methyl ether to obtain an intermediate product and subsequently drying under vacuum. Form III may be prepared by crystallizing/recrystallizing amorphous Bromfenac sodium, Form I and/or Form II or mixtures thereof from a mixture of water and at least one alcohol, preferably ethanol. Form III may also be prepared by hydrating Form II.
Device and method for X-ray fluorescence analysis of contrast agent dispersion, comprises an X-ray source (1) and a beam collimator (2). A radial arrangement of collimator blades (8) is oriented on the primary beam. The X-ray with small or vanishing angular deviation passes through a radial direction. The multiply scattered X-rays (9) are absorbed by the collimator blades. The collimated X-rays (3) pass through the object, which is to be examined. The object, which is to be examined, comprises the contrast agent dispersion, which is a contrast agent with high atomic number. Device and method for X-ray fluorescence analysis of contrast agent dispersion, comprises an X-ray source (1) and a beam collimator (2). A radial arrangement of collimator blades (8) is oriented on the primary beam. The X-ray with small or vanishing angular deviation passes through a radial direction. The multiply scattered X-rays (9) are absorbed by the collimator blades. The collimated X-rays (3) pass through the object, which is to be examined. The object, which is to be examined, comprises the contrast agent dispersion, which is a contrast agent with high atomic number. The contrast agent dispersion stimulates the emission of X-rays with certain energy along the beam through the X-ray fluorescence. The radially outwardly extending X-rays of X-ray fluorescence passes through the arrangement of collimator blades and reflects from an arrangement of monochromator crystals. The crystal planes are arranged and molded relative to the collimator blades such that the condition for the reflection angle required for the reflection of X-rays of certain energy to the monochromator crystal is satisfied. The X-rays with dependent fluorescence energy are reflected by the contrast agents. The reflected X-rays are detected without spatial resolution by a simple large-scale X-ray detector. An independent claim is also included for an image formation by rotation of the device around an axis in the object and by displacement of the device perpendicular to this axis, comprising collecting data over the contrast agent dispersion by the rotation and displacement of the device around the object during the X-ray fluorescence analysis and producing images of the contrast agent dispersion using the data with known computer tomographic method.
Eligible participants will be linked to a peer support specialist. Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with opioid use disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for 3 months post-baseline utilizing the newly validated checklist.
Researchers evaluated serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies in patients hospitalized for COVID-19 infection. The researchers evaluated the results of white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in Covid-9 patients.
Three cycles of Tislelizumab in conjunction with platinum-based chemotherapy were administered at three-week intervals. Surgical intervention was subsequently scheduled to occur within 4 to 6 weeks (±7 days) following the completion of the third chemotherapy cycle.
Cardiovascular disease (CVD) affects nearly 1 in 2 U.S. adults, is the #1 killer of men and women, burdens disadvantaged groups, and has costs greater than any other condition. While these statistics highlight the importance of CVD prevention, current approaches have only partial effectiveness. This has created a need to identify new CVD prevention targets, their underlying mechanisms, and effective interventions. Insomnia, its candidate mechanisms, and insomnia treatment are strong candidates in this regard. Thirty years of evidence indicates that insomnia is an independent, clinically important, robust, and potentially causal and modifiable risk factor for CVD. In addition, biologically plausible mechanisms that could explain how insomnia promotes the development of CVD have been proposed, with the most strongly supported being systemic inflammation, autonomic dysfunction, and metabolic dysregulation. Because insomnia now receives limited attention in settings where CVD prevention occurs (e.g., primary care), there is a large cohort of patients with an unaddressed CVD risk factor (insomnia). This status quo and the strong state of the insomnia-to-CVD science create the current need for a well-powered, mechanistic trial to elucidate biological mechanisms underlying the insomnia-to-CVD relationship and the mechanisms of action of cognitive-behavioral therapy for insomnia (CBT-I), both of which are presently unknown. Therefore, we are conducting a mechanistic trial of 200 primary care patients (45% minority) with insomnia and CVD risk factors but no clinical CVD. Participants will be randomized to 6 months of the SHADES (Strengthening Hearts by Addressing DisruptEd Sleep) intervention or the active control condition. The SHADES intervention is our modernized collaborative care intervention consisting of well-established internet, telephonic, and/or face-to-face CBT-I. The active control condition consists of sleep education/hygiene, symptom monitoring, and primary care for insomnia. Our proposal has four aims - Aim 1: determine the effect of the SHADES intervention on our primary CVD mechanism of high-sensitivity CRP; Aim 2: determine the effect of the SHADES intervention on our secondary CVD mechanisms of systemic inflammation, autonomic dysfunction, and metabolic dysregulation; Aim 3: examine if 6-month improvements in upstream sleep mechanisms mediate the SHADES intervention effect on 6-month improvements in downstream CVD mechanisms; Exploratory Aim: explore the effect of the SHADES intervention on proinflammatory gene expression. This trial could generate the critical support for the mechanistic rationale and conceptual framework needed to justify the next-step phase III, multi-site clinical trial to determine the SHADES Intervention effect on CVD clinical outcomes, endpoints of great public health relevance, morbidity, and cost.
The senior is given an assistive device that is managed remotely by the caregiver. It is as small as practically possible and is worn on the wrist or as a pendant, clipped on a belt or fastened elsewhere on the body. It carries out several functions that help the senior, including automatic reminders and compliance checking. It uses digitized speech to provide information to the user. Through a wireless connection, the assistive device is programmed and monitored remotely by the caregiver via the caregiver web portal. The caregiver specifies all reminders to be programmed into the assistive device and can view current and historical senior acknowledgements, senior notifications including medicine compliance, and device operational state. The caregiver can remotely program the device to have senior notifications forwarded to any caregiver messaging address such as an email address, cell phone number as a text message or even as an instant message.
The invention belongs to the technical field of medicaments, and relates to a series of novel daphnane diterpene compounds, namely Genkwanine II, Genkwanin III, Genkwanin IV, Genkwanin V, Genkwanin VI, and Genkwanin VII which are extracted and separated from buds of Daphne genkwa, zucc. The compounds have the same daphnane diterpene parent nucleus and a chemical structural general formula shown in a formula (1). The invention also relates to new compounds, the antitumor physiological activity of medicaments prepared by the new compounds, and pharmaceutical application of the new compounds. The compounds can be combined with pharmaceutically acceptable carriers to prepare into clinically acceptable dosage forms to be used for the treatment of various cancers. A method for preparing the compounds has the advantages of simplicity, good reproducibility, and high extraction purity. The compounds have better antitumor activity effect.
Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
Rituximab, alone or as a component of the Zevalin therapeutic regimen, can cause severe, including fatal, infusion reactions. These reactions typically occur during the first rituximab infusion with time to onset of 30 to 120 minutes. Signs and symptoms of severe infusion reactions may include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock. Temporarily slow or interrupt the rituximab infusion for less severe infusion reactions. Immediately discontinue rituximab and Y-90 Zevalin administration for severe infusion reactions. Only administer rituximab/Zevalin in facilities where immediate access to resuscitative measures is available [see Boxed Warning and Dosage and Administration (2.2)]. See also prescribing information for rituximab.
Recent advances in genomic techniques are making possible a new wave of genetic discovery in congenital heart disease (CHD). Existing data suggests that CHD occur in Sub-Saharan Africa at frequencies similar to the rest of the world. In this application, we propose to utilize the unique advantages of Sub-Saharan Africa - a combination of the most genetically diverse populations in the world and of diminished environmental background effects (i.e. low prevalence of smoking, alcohol abuse, obesity in comparison to western countries) - to better understand the genetic basis for congenital heart disease. We will couple next generation genomic techniques with more traditional gene discovery methods to investigate CHD in two African countries: Uganda and Nigeria. The inclusion of syndromic and non-syndromic CHD observed in these populations as well as careful phenotyping (including echocardiography) will greatly enhance our potential to provide insight into the genetic architecture of CHD in African populations. To accomplish this, we plan to enroll families, in whom members have congenital heart malformations consistent with an error of early human development in our research protocol. Patients will be enrolled at the Uganda Heart Institute in Kampala, Uganda, and at the Department of Pediatrics, College of Medicine, University of Lagos, Nigeria, with the potential to include other African sites. High throughput genomic studies will be done at the NIH.
Immersive virtual reality (i-VR) is a powerful tool that can be used to explore virtual models in three dimensions. It could therefore be a valuable tool to supplement anatomical teaching by providing opportunities to explore spatial anatomical relationships in a virtual environment. However, there is a lack of consensus in the literature as to its effectiveness as a teaching modality when compared to the use of cadaveric material. The aim of our study was to compare the effectiveness of i-VR in facilitating understanding of different anatomical regions when compared with cadaveric prosections for a cohort of first- and second-year undergraduate medical students. Students (n = 92) enrolled in the MBBS program at Queen Mary University of London undertook an assessment, answering questions using either Oculus i-VR headsets, the Human Anatomy VR™ application, or prosection materials. Utilizing ANOVA with Sidak's multiple comparison test, we found no significant difference between prosections and i-VR scores in the abdomen (p = 0.6745), upper limb (p = 0.8557), or lower limb groups (p = 0.9973), suggesting that i-VR may be a viable alternative to prosections in these regions. However, students scored significantly higher when using prosections when compared to i-VR for the thoracic region (p < 0.0001). This may be due to a greater need for visuospatial understanding of 3D relationships when viewing anatomical cavities, which is challenged by a virtual environment. Our study supports the use of i-VR in anatomical teaching but highlights that there is significant variation in the efficacy of this tool for the study of different anatomical regions.
Ischemia-reperfusion (IR) causes tissue injury. Preclinical animal data suggest that ticagrelor but not clopidogrel protects against IR injury due to inhibition of cellular adenosine uptake and NO-synthase stimulation. It is unclear if this action is part of the beneficial clinical effect of ticagrelor in patients with a history of acute coronary syndrome. The preventive action of ticagrelor on IR injury may also be of interest for the peripheral vasculature, where IR injury is known to result in endothelial dysfunction. This study aims to investigate if treatment with ticagrelor can mitigate the transient loss of endothelium-dependent vasodilatation of the resistance vasculature following a short period of ischemia, compared with clopidogrel at standard clinical doses. We will study the effect of ticagrelor or clopidogrel after a loading dose and after a two weeks period of regular intake on forearm blood flow (FBF) reactivity in response to the vasodilators acetylcholine (ACh; endothelium-dependent agonist) or nitroglycerin (GTN; endothelium-independent vasodilator) before and 10 min after a 20 min forearm ischemia, respectively
All patients assisted by the palliative care center (hospice and home) will receive the oral hygiene protocol and the propolis-based product. The oral hygiene protocol will be applied starting from the day of taking care of the patient in the service and until discharge / death. Administration of the study product will be continued for 2 weeks or stopped sooner if the patient loses the ability to swallow.
Novel genes and vectors exhibiting increased expression and novel splicing patterns are disclosed. The gene can comprise one or more consensus or near consensus splice sites which have been corrected. The gene can alternatively or additionally comprise one or more introns within coding or noncoding sequences. The gene can still further comprise modified 5' and/or 3' untranslated regions optimized to provide high levels and duration of tissue-specific expression. In one embodiment, the gene comprises the coding region of a full-length Factor VIII gene modified by adding an intron within the portion of the gene encoding the beta-domain, so that the gene is expressed as a beta-domain deleted Factor VIII protein. The novel Factor VIII gene can also be modified to correct one or more consensus or near consensus splice sites within or outside of the coding region.
To show that early diagnosis of SCID with a TREC screening assay can warrant timely treatment of the disease and avoid life-threatening infections on patients. Babies with SCID are unable to fight infections. They become severely ill in their first months of life and do not survive unless their immune systems can be restored. SCID can be treated by bone marrow transplant if recognized early. The newborn screening test to be employed in this study is designed to diagnose SCID before infections occur. By conducting a pilot testing program in a high-risk population on the Navajo Indian Reservation, where one in 2,000 infants is born with SCID, we hope to confirm the benefits of newborn screening for early diagnosis of SCID
A computer-implemented method for obtaining health-related data at a user device is disclosed. A data collection application for obtaining health-related data is run at the user device. The data collection application supports data collection in a multiple data collection modes, including a sensor-based data collection mode for receiving health-related data from one or more sensors included in or in communication with the user device, a user data input mode for obtaining health-related data based on user input of a configurable set of one or more health-related data values; and an interactive health assessment mode for executing configurable interactive assessments for obtaining health-related data based on user interaction with the user device. The user device receives, over a communications network, a data collection configuration from a health monitoring system, the data collection configuration specifying a plurality of data collection activities to be performed at the user device, each data collection activity for obtaining respective health-related data and associated with at least one of the plurality of data collection modes. Each data collection activity is performed by the data collection application in accordance with the associated data collection mode to obtain health-related data. Result data, including sensor data, user input data, and/or interactive assessment data, is transmitted to the health monitoring system based on the obtained health-related data.
The purpose of this study was to investigate whether jacket wearing by semi-indoor Holstein calves affected performance, body measurements and health status in the preweaning period throughout the winter months. A total of one hundred calves were allocated into two treatment groups (control and jacket) in terms of their weights and sex. The calves throughout the study period were raised at individual calf hutches in a semi-open barn. All calves and the consumed concentrate intakes were weighed every 28 days to determine body weight (BW), average daily gain (ADG), total and daily feed consumption (TFC, DFC). Incidence rate (IR) ratios were calculated from the records of daily health assessments. Calves in treatment group were jacketed from first to 45 days of age. The weaning process started gradually at 56 days of age and the calves were weaned on day 63. No significant effects of wearing jackets in terms of body measurements and performance. The respiratory diseases IR was 1.15 times higher in calves without jackets, which means that calf health was positively affected by wearing jackets. The improved health status of the treatment group showed that wearing jackets may protect calves from adverse effects of cold stress. There is a need for more comprehensive studies about the effect of calf jackets in early periods of preweaning, especially in calves in outdoor hutches.